Analyst Consensus ?
ConsensusBuy27 ratings
Bullish2488.9%
Neutral311.1%
Bearish00.0%
FN2 Earnings Intelligence
BridgeBio Pharma, Inc. analyst ratings
BridgeBio Pharma, Inc. (BBIO) analyst consensus, price targets, and firm-level rating history from FN2 Research.
Analyst 52W Price Targets
$66.58Current
$17Low
$87.47Average
$157High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Sep 21, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | Maintain | Sep 10, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Sep 1, 2026 |
| Truist Securities | Buy | Buy | Maintain | Aug 12, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Aug 12, 2026 |
| Canaccord Genuity | Buy | Buy | Maintain | Aug 12, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Aug 11, 2026 |
| TD Cowen | Buy | Buy | Maintain | Aug 11, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Aug 11, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Aug 11, 2026 |
| B of A Securities | Buy | Buy | Maintain | Aug 11, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Jul 16, 2026 |
| Raymond James | Market Perform | Outperform | Downgrade | May 26, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | May 8, 2026 |
| Oppenheimer | Outperform | Outperform | Maintain | Feb 25, 2026 |
| Leerink Partners | Outperform | Outperform | Maintain | Dec 15, 2025 |
| Goldman Sachs | Buy | Buy | Maintain | Oct 31, 2025 |
| Cantor Fitzgerald | Overweight | Overweight | Maintain | Oct 30, 2025 |
| UBS | Buy | Buy | Maintain | Sep 12, 2025 |
| Scotiabank | Sector Outperform | Sector Outperform | Maintain | Aug 6, 2025 |
| Jefferies | Hold | Buy | Downgrade | Jul 18, 2023 |
| SVB Securities | Outperform | Outperform | Maintain | Apr 13, 2023 |
| Cowen & Co. | Outperform | Outperform | Maintain | Feb 6, 2023 |
| SVB Leerink | Outperform | Outperform | Maintain | Jan 23, 2023 |
| BTIG | Buy | Buy | Maintain | May 19, 2020 |
| H.C. Wainwright | Buy | Buy | Maintain | Apr 13, 2020 |
| Piper Jaffray | Overweight | Overweight | Maintain | Jul 22, 2019 |
| BMO Capital | Outperform | Outperform | Maintain | Jul 22, 2019 |
Named analyst price targets
Upside is calculated against the persisted current price $66.58. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Mizuho Securities | Analyst unavailable | $110 | $76.59 | +65.2% | Sep 1, 2026 |
| Truist Financial | Danielle Brill | $107 | $83.89 | +60.7% | Aug 12, 2026 |
| Canaccord Genuity | Analyst unavailable | $106 | $83.7 | +59.2% | Aug 12, 2026 |
| Cantor Fitzgerald | Josh Schimmer | $110 | $84.72 | +65.2% | Aug 11, 2026 |
| Morgan Stanley | Sean Laaman | $97 | $84.67 | +45.7% | Aug 11, 2026 |
| Wells Fargo | Derek Archila | $102 | $84.67 | +53.2% | Aug 11, 2026 |
| Piper Sandler | Analyst unavailable | $115 | $84.67 | +72.7% | Aug 11, 2026 |
| H.C. Wainwright | Analyst unavailable | $120 | $85.89 | +80.2% | Jul 13, 2026 |
| Mizuho Securities | Salim Syed | $96 | $68 | +44.2% | Jun 16, 2026 |
| Canaccord Genuity | Analyst unavailable | $104 | $63.88 | +56.2% | Jun 3, 2026 |
| Morgan Stanley | Analyst unavailable | $98 | $65.59 | +47.2% | May 28, 2026 |
| H.C. Wainwright | Analyst unavailable | $110 | $67.39 | +65.2% | May 11, 2026 |
| Evercore ISI | Analyst unavailable | $130 | $66.53 | +95.3% | May 8, 2026 |
| Bernstein | Analyst unavailable | $114 | $67.45 | +71.2% | May 8, 2026 |
| Truist Financial | Danielle Brill | $102 | $70.08 | +53.2% | Apr 29, 2026 |
| RBC Capital | Luca Issi | $100 | $74.14 | +50.2% | Apr 8, 2026 |
| Leerink Partners | Mani Foroohar | $98 | $68.77 | +47.2% | Mar 12, 2026 |
| Truist Financial | Danielle Brill | $95 | $65.75 | +42.7% | Feb 25, 2026 |
| H.C. Wainwright | Raghuram Selvaraju | $100 | $75.25 | +50.2% | Feb 17, 2026 |
| Tudor Pickering | William Pickering | $100 | $76.59 | +50.2% | Feb 13, 2026 |
| Oppenheimer | Trevor Allred | $83 | $76.22 | +24.7% | Feb 13, 2026 |
| Jefferies | Andrew Tsai | $100 | $76.06 | +50.2% | Feb 12, 2026 |
| Raymond James | Martin Auster | $89 | $77.74 | +33.7% | Feb 12, 2026 |
| Barclays | Analyst unavailable | $157 | $77.87 | +135.8% | Jan 27, 2026 |
| Wells Fargo | Tiago Fauth | $88 | $76.26 | +32.2% | Jan 20, 2026 |
| Truist Financial | Analyst unavailable | $86 | $74.27 | +29.2% | Jan 8, 2026 |
| Morgan Stanley | Analyst unavailable | $96 | $73.42 | +44.2% | Jan 6, 2026 |
| Leerink Partners | Analyst unavailable | $86 | $74.59 | +29.2% | Dec 15, 2025 |
| Bernstein | Analyst unavailable | $94 | $72.7 | +41.2% | Dec 11, 2025 |
| Truist Financial | Analyst unavailable | $80 | $63.88 | +20.2% | Oct 30, 2025 |
| Oppenheimer | Analyst unavailable | $81 | $64.38 | +21.7% | Oct 30, 2025 |
| Piper Sandler | Analyst unavailable | $98 | $66.62 | +47.2% | Oct 30, 2025 |
| Goldman Sachs | Paul Choi | $100 | $66.62 | +50.2% | Oct 30, 2025 |
| H.C. Wainwright | Analyst unavailable | $90 | $65.73 | +35.2% | Oct 29, 2025 |
| H.C. Wainwright | Analyst unavailable | $80 | $63.33 | +20.2% | Oct 28, 2025 |
| Raymond James | Analyst unavailable | $69 | $63.2 | +3.6% | Oct 27, 2025 |
| Leerink Partners | Mani Foroohar | $68 | $63.61 | +2.1% | Oct 27, 2025 |
| H.C. Wainwright | Raghuram Selvaraju | $70 | $51.5 | +5.1% | Aug 29, 2025 |
| UBS | Eliana Merle | $72 | $38.36 | +8.1% | Apr 30, 2025 |
| Citigroup | David Lebowitz | $45 | $24.17 | -32.4% | Oct 24, 2024 |
| Leerink Partners | Mani Foroohar | $46 | $26.34 | -30.9% | Oct 17, 2024 |
| Piper Sandler | Biren Amin | $46 | $28.78 | -30.9% | Sep 11, 2024 |
| Mizuho Securities | Salim Syed | $53 | $29.92 | -20.4% | Sep 3, 2024 |
| Raymond James | Danielle Brill | $46 | $22.64 | -30.9% | Jun 24, 2024 |
| BMO Capital | Kostas Biliouris | $37 | $26.92 | -44.4% | Jun 5, 2024 |
| Wells Fargo | Tiago Fauth | $58 | $27.13 | -12.9% | Jun 5, 2024 |
| Goldman Sachs | Paul Choi | $50 | $27.61 | -24.9% | May 30, 2024 |
| UBS | Eliana Merle | $47 | $27.94 | -29.4% | May 28, 2024 |
| H.C. Wainwright | Raghuram Selvaraju | $43 | $30.09 | -35.4% | May 20, 2024 |
| Evercore ISI | Cory Kasimov | $50 | $28.5 | -24.9% | May 13, 2024 |
| J.P. Morgan | Analyst unavailable | $19 | $9.58 | -71.5% | Nov 18, 2022 |
| Raymond James | Dane Leone | $17 | $10.76 | -74.5% | Mar 17, 2022 |
Track every rating change on BBIO the moment it posts. Free to start.
Start freeGet the BBIO recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.